Germany's Merck launches seed fund for start-ups in China

18 October 2019

German Science and pharma company Merck KGaA (MRK: DE) today announced a 100 million renminbi ($13.5 million) seed fund targeted at start-ups in China. The company also officially opened its innovation hub in Shanghai and announced plans to officially open a second innovation hub in Guangzhou in November.

“Our 100 million renminbi China seed fund underlines our commitment to invest in the Chinese market,” said Stefan Oschmann, chief executive and chairman of the executive board of Merck, at the opening ceremony in Shanghai today. “Our China innovation hubs will accelerate our innovation development nationwide. Together with local partners, we aim to jointly advance innovation in China, for China and beyond.”

Within the scope of the overall 300 million-euro ($333.6 million) corporate strategic venture arm M Ventures, the new 13 million-euro seed fund is being established to foster relevant innovations from China and to get closer to the start-up scene in China owing to the country’s commitment to innovation.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK